Preventing low blood counts with trilaciclib after chemoradiation for esophageal cancer
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system clinical trials.
This trial tests an investigational drug called trilaciclib that is given before chemoradiation to help protect your bone marrow and reduce side effects like low blood counts. It is for people with a specific type of esophageal cancer who have finished their main treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with a type of esophageal cancer called squamous cell carcinoma.
- You did not have surgery to remove the cancer.
- You have already completed a full course of chemotherapy with radiation, and possibly immunotherapy.
- You do not have any other current or past cancers (except maybe some minor skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug trilaciclib can reduce low blood cell counts caused by chemotherapy in people with Ewing's sarcoma. If you qualify, you may receive a medication that could help protect your bone marrow during treatment.
This trial tests whether taking trilaciclib alongside standard chemotherapy can help prevent low blood cell counts (myelosuppression) in people with limited-stage small cell lung cancer. It may help you stay stronger during treatment.
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
This trial tests a drug called trilaciclib, given before chemotherapy, to see if it can protect your bone marrow and help prevent dangerous drops in blood cell counts. If you have head and neck cancer that has returned or spread and haven't had prior drug treatment, this might help you stay stronger during chemo.
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
This trial tests a drug that may help protect your bone marrow during chemotherapy, possibly reducing side effects like low blood counts. It is for people with certain advanced or recurrent solid tumors who are about to start a specific chemo regimen.
Hear when a new ESCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.